Skip to content

Study · Observational study · n = 497 · 2024

4 results

Association of semaglutide treatment with coronary artery inflammation in type 2 diabetes mellitus patients: a retrospective study based on pericoronary adipose tissue attenuation.

Li Y, Yao W, Wang T, Yang Q, Song K, Zhang F, Wang F, Dang Y

Cardiovascular diabetology28 Sept 2024Cited by 16 (Europe PMC)

PMID39342279 (opens in a new tab)PMCIDPMC11439223 (opens in a new tab)DOI10.1186/s12933-024-02445-2 (opens in a new tab)PepBankPUB-39342279
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes, pericoronary fat attenuation index of the LAD and LCX was lower in semaglutide-treated patients than in untreated patients before matching.

    In plain wordsIn adults with type 2 diabetes, semaglutide treatment was linked to lower signs of heart artery inflammation in two arteries.

    Peptide
    Semaglutide
    Outcome
    DecreasePericoronary FAI of LAD and LCX before propensity matching
    Study

    n = 497

    Comparator
    Patients not treated with semaglutide
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Before PSM, pericoronary FAI of the LAD and LCX was lower in patients treated with semaglutide than those without semaglutide treatment.
    1 context sentence
    Summary · context
    This study enrolled 497 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Hebei General Hospital, of whom 93 treated with semaglutide (Sema+) and 404 did not (Sema-).
  2. 02HumanObservational studyEfficacy outcome

    In propensity-matched adults with type 2 diabetes, pericoronary FAI was lower in all three major coronary arteries in the semaglutide group than in the non-semaglutide group.

    In plain wordsIn adults with type 2 diabetes, semaglutide treatment was linked to lower signs of inflammation in all three main heart arteries.

    Peptide
    Semaglutide
    Outcome
    DecreasePericoronary FAI in three major coronary arteries after propensity matching
    Study

    n: not reported in source

    Comparator
    Patients not treated with semaglutide
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results of the PSM analysis revealed a lower FAI in all three major coronary arteries in the Sema + group compared to the Sema- group.
    1 context sentence
    Summary · context
    This study enrolled 497 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Hebei General Hospital, of whom 93 treated with semaglutide (Sema+) and 404 did not (Sema-).
  3. 03HumanObservational studyEfficacy outcome

    In multivariate linear regression, semaglutide treatment was independently associated with reduced pericoronary FAI in all three major coronary arteries.

    In plain wordsIn adults with type 2 diabetes, semaglutide treatment was linked to lower heart artery inflammation signs after adjustment for other factors.

    Peptide
    Semaglutide
    Outcome
    DecreaseIndependent association of semaglutide with pericoronary FAI
    Study

    n: not reported in source

    Comparator
    Patients not treated with semaglutide
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Multivariate linear regression analyses revealed an independent association between semaglutide treatment and reduced FAI in all three major coronary arteries.
    1 context sentence
    Summary · context
    This study enrolled 497 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Hebei General Hospital, of whom 93 treated with semaglutide (Sema+) and 404 did not (Sema-).
  4. 04HumanObservational studyEfficacy outcome

    The association between semaglutide and lower FAI varied across patients with type 2 diabetes of differing profiles.

    In plain wordsIn adults with type 2 diabetes, the link between semaglutide and lower artery inflammation signs differed between patient groups.

    Peptide
    Semaglutide
    Outcome
    MixedVariation of the FAI association across patient profiles
    Study

    n: not reported in source

    Comparator
    Patients not treated with semaglutide
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    This association varied across T2DM patients of differing profiles.
    1 context sentence
    Summary · context
    This study enrolled 497 T2DM patients who underwent coronary computed tomography angiography (CCTA) at Hebei General Hospital, of whom 93 treated with semaglutide (Sema+) and 404 did not (Sema-).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.